Clinical trial ARASENS
A randomized, double blind, placebo controlled Phase III study of ODM 201 versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone sensitive prostate cancer
| Cancers | |
|---|---|
| Organ | prostate |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Bayer |
| EudraCT Identifier | 2015-002590-38 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT02799602 |
| Inclusion criteria | Metastatic |
| Last update |